These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8735716)

  • 61. High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma.
    Lee CT; Wu TT; Lohse CM; Zhang L
    Hum Pathol; 2014 Nov; 45(11):2334-40. PubMed ID: 25245603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.
    Matsushima H; Kuroki T; Kitasato A; Adachi T; Tanaka T; Hirabaru M; Hirayama T; Kuroshima N; Hidaka M; Soyama A; Takatsuki M; Kinoshita N; Sano K; Nishida N; Eguchi S
    Dig Liver Dis; 2015 Dec; 47(12):1067-75. PubMed ID: 26341967
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
    Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
    Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
    Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
    Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
    Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
    Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of transforming growth factor betas and their signaling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma.
    Lee KT; Liu TS
    World J Surg; 2003 Oct; 27(10):1143-8. PubMed ID: 12917766
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intrahepatic cholangiocarcinoma with predominant ductal plate malformation pattern.
    Choe JY; Kim H
    Clin Mol Hepatol; 2014 Jun; 20(2):214-7. PubMed ID: 25032189
    [No Abstract]   [Full Text] [Related]  

  • 69. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis.
    Ohta T; Nagakawa T; Ueda N; Nakamura T; Akiyama T; Ueno K; Miyazaki I
    Cancer; 1991 Nov; 68(10):2217-23. PubMed ID: 1655206
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
    Washington K; Gottfried MR
    Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading.
    Nakajima T; Kondo Y; Miyazaki M; Okui K
    Hum Pathol; 1988 Oct; 19(10):1228-34. PubMed ID: 2844646
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y
    Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of ABH and Lewis blood group antigens in combined hepatocellular-cholangiocarcinoma. Possible evidence for the hepatocellular origin of combined hepatocellular-cholangiocarcinoma.
    Okada Y; Jinno K; Moriwaki S; Morichika S; Torigoe S; Arima T; Nagashima H; Koprowski H
    Cancer; 1987 Aug; 60(3):345-52. PubMed ID: 3036328
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
    Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
    Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.
    Aishima S; Oda Y
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):94-100. PubMed ID: 25181580
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with otherwise node-negative hilar cholangiocarcinoma.
    Tojima Y; Nagino M; Ebata T; Uesaka K; Kamiya J; Nimura Y
    Ann Surg; 2003 Feb; 237(2):201-7. PubMed ID: 12560778
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts.
    Itatsu K; Zen Y; Yamaguchi J; Ohira S; Ishikawa A; Ikeda H; Sato Y; Harada K; Sasaki M; Sasaki M; Sakamoto H; Nagino M; Nimura Y; Ohta T; Nakanuma Y
    Hum Pathol; 2008 May; 39(5):710-9. PubMed ID: 18329694
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neoexpression of Lewis Y antigen is a sensitive phenotypic change of the damaged intrahepatic bile ducts.
    Sasaki M; Kono N; Nakanuma Y
    Hepatology; 1994 Jan; 19(1):138-44. PubMed ID: 7903952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.